ASX Announcement

Melbourne, 25 August 2011

CogState signs sales contract for phase 3 study

Highlights

- CogState signs contract to be used in phase 3 clinical trial for treatment of Major Depressive Disorder
- The contract will generate US$1.10m of revenue over the study duration
- Total value of clinical trials sales contracts signed since 1 July 2011 is US$1.7m
- Including this contract, CogState has secured US$5.2m of revenue that is expected to be recognised in the 2012 financial year and a further US$2.0m that will be recognised in subsequent periods

CogState Ltd (ASX:CGS) today announced that it has signed a contract with an international pharmaceutical company to participate in a phase 3 clinical trial for the treatment of Major Depressive Disorder.

Under the contract, which will generate US$1.10 million of revenue for CogState over the study duration, CogState will provide its cognitive testing technology and associated services to 600 patients located in 70-75 sites around the world. The CogState computerized cognition testing software, and associated on-line site training materials, will be provided in 15 languages.

Cognition, as measured by the CogState computerized tests, will be a secondary endpoint in the study.

This is the second large clinical trial for the treatment of Major Depressive Disorder that CogState has signed in the last three months. In May 2011, CogState announced a US$1.55 million contract, with a different pharmaceutical company, to participate in a phase 2 clinical trial for the treatment of Major Depressive Disorder.

CogState reported in May that, according to data compiled from clinicaltrials.gov, there were 1,395 clinical trials focused on the therapeutic area of Depression in active registration, with 585 new trials started per year (based on the average of 2008-2010 data). CogState estimates that approximately 10% of such studies will seek to measure the cognitive effect of the compound under review.

Since 1 July 2011, CogState has signed sales contracts to the value of US$1.7 million, including the above mentioned contract.

CogState currently has US$7.2 million of contracted revenue that will be recognised in future periods – an improvement of US$3.0 million from the same time last year.

Of the US$7.2 million of contracted revenue, CogState expects US$5.2 million to be recognised in the 2012 financial year – an improvement of US$1.6 million from the same time last year.

About CogState

CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). To date, CogState has commercialised its technology in two markets – clinical drug trials and concussion management in sport.

In the clinical drug trial market, CogState technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Otsuka, and Servier.

In the area of sports related concussion, CogState's technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. That technology is now marketed to consumers as Axon Sports. Current users of CogState/Axon Sports include, University of Notre Dame, University of Michigan, University of Connecticut, English Rugby League, English Jockey Club, and a number of national and international Rugby League and Rugby Union clubs. In Australia, both the AFL and NRL have mandated computerised cognitive testing, using CogState.

For further information:

Brad O'Connor, Chief Executive Officer, CogState Ltd.
Ph: 03 9664 1300 Mob: 0411 888 347 boconnor@cogstate.com